INTRODUCTION
The use of theragnostic nanoparticles (TNPs) for malignancy treatment is one of the most leading-edge biotechnology research topics. [1] [2] [3] The resulting-nanoplatform is optimized in the precise diagnosis of disease, individualized treatment and real-time monitoring of therapeutic outcomes. 4 For clinically relevant applications in oncology, TNPs with absorption in the near-infrared (NIR) (700-900 nm) is particularly attractive, because the transparency window for biological tissues allows for deeper light penetration and relatively low absorption/scattering, and thereby can efficiently transfer the absorbed NIR optical energy into heat. 5, 6 A series of nanomaterials including zinc oxide nanoparticles (ZnO NPs), 7, 8 graphene oxide (GO), 9 ,10 carbon nanotubes (CNTs), 11 carbon dots (CDs), 12 and gold nanoparticles (AuNPs) 13, 14 have been applied for photothermal therapy (PTT) as their strong absorbance in the NIR region. Recently, many researchers have explored the role of GO sheets as the theranostic agent in PTT in vitro and in vivo. 15 The delocalized electron arrangement makes GO capable of absorbing NIR radiation. The absorbed radiation can derive from various GO vibrational modes that are further transferred into thermal energy, leading to the high temperature around cancerous tissue, structural changes in cellular, as well as protein configurations. 9, 10 Owing to the excellent thermal conductivity (59.2%) and high effective surface area (90.6 m 2 /g), GO sheets have served as one of the most effective nanomaterials for PTT applications. 9, 10, 15, 16 In fact, biocompatibility has always been regarding as one of the most important parameters for graphene-based nanomaterials applications in (especially in vivo) photothermal therapy of cancer cells. Cytotoxicity of GO nanosheets exhibits dose-dependent property, 17, 18 which suggests that biocompatible GO nanosheets should be constructed to reduce cytotoxicity. This reduction can be obtained by preparing a hierarchical GO nanocomposites (NCs). 15 To date, thanks to distinct physical and chemical properties,
AuNPs have been used as biological safe materials for a variety of biomedical applications such as drug delivery, imaging, biosensing and therapy. 19, 20 AuNPs have strong absorption in the NIR region because they exhibit a localized surface plasmon resonance band and throughout the NIR region. 21, 22 Therefore, AuNPs have been applied as promising photothermal agents for cancer treatments. Furthermore, AuNPs can be easily synthesized and chemically modified. These allow the further development of a NCs by the assembly of AuNPs on GO nanosheets in the pursuit of a broad light absorption band and excellent photothermal effect.
Chemotherapy, surgery and radiotherapy treatments of cancer have strong side effects for living beings. [23] [24] [25] Therefore, in the process of later clinical treatment, improving the drug targeting, enhancing the drug curative effect while minimizing adverse drug side effects are needed. 26, 27 ZnO NPs have been widely used in biocidal applications, sensor designing, catalysis and gas sensing; however, these nanostructures in drug delivery system are still in a nascent stage. [28] [29] [30] Most recently, ZnO NPs have been explored as nano-vectors for targeted drug delivery systems, behaving as (1) biological modification, 31 or (2) ZnO NPs based drug delivery system. 32 For example, ZnO NPs had been demonstrated for multimodal cancer treatment through loading antitumor drug (DOX). 33 The combination of ZnO NPs and DOX gave rise to a synergistic therapy, which was presumed due to the controlled-release of Zn 2+ and DOX in the tumor microenvironment where the acidic condition (pH < 5.5) triggered the decomposition of ZnO from the NCs. 34 Such dissolution behavior of ZnO NPs has been well investigated. ZnO NPs were found to possess significant cytotoxic effects, if and only if post dissolving preferentially killed cancer cells. These excellent properties have propelled the recent development of the pH-sensitive ZnO NPs for drug delivery. 35, 36 Latest reports have shown that ZnO nanosheet was used as the bifunctional vector for chemo-photothermal therapy. 35 However, only few ZnO structures like that has been found in cancer therapy. 7, 37 For example, ZnO nanodots/nanosheet structures easily aggregated and ZnO nanotubes/pyramids/hexagon/cages hasn't been reported. It is important for effective cancer therapy to select a ZnO nano-structure for targeting tumor site with high drug loading efficiency and releasing payload to the cancer cells. 38 Taken together, we present a one-step process that uses free-base L-histidine (His) to mediate the growth of continuous and uniform shells of either amorphous ZnO on AuNPs in aqueous solutions (denoted as Au-His@a-ZnO). The use of L-histidine can benefit to not only construct monodisperse and unaggregated core-shell colloids, but also precisely tune the shell thickness to 2.5 nm, thereby meeting the requirements of plasmonic particles with either ultrathin or customizable coatings for biological applications. 39 Instruments and Characterization. The photoluminescent (PL) spectra were recorded using molecular fluorescence spectrometer (Cary Eclipse, Varian, USA).
Nexus 670 FTIR type (Nicolet) infrared spectrometer was used to analyze the infrared spectrum. The X-ray diffraction (XRD) analysis was performed using a D/Max 2500V/PC diffractometer (Rigaku Corporation, Japan). Ultraviolet-Visible (UV-Vis) absorption spectra were recorded using UV spectra (Cary-50, Varian, USA). The surface composition and element analysis were recorded using X-ray photoelectron spectroscopy (XPS, EscaLab-250, Thermo, USA). The morphologies of the samples 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 and elemental analyses were characterized using the transmission electron microscope (TEM, H-7650, Hitachi, Japan) and energy dispersive X-ray spectroscopy (EDS, H-7650, Hitachi, Japan). In vitro bright field and fluorescence images were performed with a laser scanning confocal microscope (LSCM, LTI-EA1R, Nikon, Japan). The specific surface area was carried out using a Brunauer-Emmett-Teller (BET, Belsorp mini II, Japan). To monitor the temperature changes at the tumor site during irradiation, infrared thermal images were recorded with a PTT monitoring system MG33 (Shanghai Magnity Electronics Co. Ltd). The methods used for material characterization were displayed in the "Experimental Section" (Supplementary File).
RESULTS AND DISCUSSION
Synthesis and Characteristics of the Au-His@a-ZnO NPs. An aqueous solution of His was mixed with a replaceable colloid of citrate-capped AuNPs (AuNPs-Cit), followed by adding NH4OH and ZnCl2. The added His caused no change to the color of the aqueous solution (red) ( Figure 1A ), indicating that well dispersed AuNPs colloids were stabilized by the His that had strong affinity to displace Cit from the gold surface as shell precursor ions ( Figure S1 ). The observations are in line with the previous study, 39 which reported His possessed the strongest affinities for the gold surface. 40, 41 The synthesis process is illustrated in Figure 1A to show the formation of AuNPs. As long as the new materials were formed, the excess amount of His continued to stabilize the particles. This is due to that His has sufficient affinity to displace Cit from the surface of AuNPs and stabilize the particles in the presence of the shell precursor ions. Au-His@a-ZnO NPs.
A number of techniques were taken to characterize each core-shell material. the XRD spectra ( Figure 1B ) revealed that the crystalline component in His-mediated shells is the gold core. Elemental analyses by XPS ( Figure 1C ) and EDS ( Figure 1D The lattice fringes in AuNPs core without crystallinity are observed by the high-resolution TEM (HRTEM) in Figure 1E , a, indicating the amorphous structure of the shell. TEM elemental mapping of His-mediated particles in Figure 1E , b clearly
shows that the shell is composed of O and Zn elements. The TEM images in Figure   1E , b demonstrate that uniform and continuous shells with thicknesses of 2.5 nm can be grown on individual AuNPs. The XPS scans of the O 1s and Zn 2p3/2 peaks shown in Figure S2 reveal that the binding energies correspond with ZnO rather than Zn(OH)2. All these characterization data indicate that His mediates the growth of a-ZnO shells on AuNPs. The nitrogen peak in XPS spectra ( Figure 1C ) confirm that the His molecules exist on the AuNPs shell surface.
Synthesis and Characterization of the GO@Au-His@a-ZnO NCs. GO nanosheets were synthesized from graphite powders by a modified Hummers method. 42 Functional groups, such as -OH and -COOH on GO nanosheets, are beneficial for their dispersion in aqueous solution ( Figure 2A ). The structures and morphologies of GO nanosheets are fully characterized by atomic force microscope (AFM) and TEM images in Figure S3 and Figure 2B . The thickness of GO nanosheets is about 0.8 nm, indicating the majority of GO nanosheets exists as monolayer structure ( Figure S3 ). TEM images in Figure 2B shows that the most GO nanosheets are ca 100 nm in lateral width. In order to obtain multimodal therapeutic functions, Au-His@a-ZnO NPs, Au-His@a-ZnO NPs as both photothermal agent and carriers for photothermal agent, were covalently grafted with PEGylated GO (GO-PEG) via amide coupling, as illustrated in Figure 2A . GO-PEG was obtained by grafting amino carboxylic PEG with GO sheet, and the left -COOH groups at the PEG terminals were available for loading Au-His@a-ZnO NPs. Such PEG functionalization was proved by FI-IR ( Figure S4 ).The morphology of GO-PEG was presented by TEM ( Figure 2C) and AFM ( Figure S5 ). GO-PEG was almost single layered sheet with average topographic height of 1.6 nm, as shown in Figure S5 . The formation of GO@Au-His@a-ZnO NCs was first verified by TEM measurements. Figure 2D showed a typical TEM image of the as-prepared GO@Au-His@a-ZnO NCs, in which Au-His@a-ZnO NPs with a narrow size distribution were deposited uniformly on the GO nanosheets surface while no aggregated Au-His@a-ZnO nanoclusters or bigger Au-His@a-ZnO NPs could be observed. Furthermore, the modification of Au-His@a-ZnO NPs to the GO surface was also confirmed by XPS. Figure S6 demonstrates that Au 4f peaks clearly occurred at 83.2 and 87.9 eV, 40 obtaining a value of 38% ( Figure S8 ), which is higher than that of the previously reported Au nanostars, 44 CDs, 45 AuNPs, 6 and Cu2-xSe NPs. 46 This improved η value makes GO@Au-His@a-ZnO as a promising photothermal coupling agent. In addition, the η value of GO nanosheets and Au-His@a-ZnO NPs was determined to be 41% and 29% (Table S1 ), suggesting that the compositions can be finely-tuned for the optimal photothermal effect. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 human cervical cancer (HeLa) and human pulmonary adenocarcinoma (A549) cell lines. This pronounced cytotoxicity to cancer cells is due to the accelerated dissolution of free Zn 2+ ions in the tumor environment, which is consistent with the previous findings in other ZnO NPs. 31, 32 As shown in Figure 3B , there is no significant hemolysis (<5%) when GO@Au-His@a-ZnO NCs were cocultured with red blood cells. In vivo biocompatibility evaluation is a key index for clinical application of nanomaterials. We measured the activated partial thromboplastin time (APTT) and prothrombin time (PT) of blood collected from rats, 24 h after intravenously injecting 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 GO@Au-His@a-ZnO NCs. The APTT and PT data for the rats injected with GO@Au-His@a-ZnO NCs were not significantly different from the control group, as shown in Figure 3C and the loaded drugs are released in the acidic microenvironment ( Figure 4A ).
For the DOX-loaded NPs, we speculated that DOX was loaded onto Figure 4B and Figure 4C . Notably, the UV absorption peak of is close to that of aptamer-conjugated carbon hollow nanoshells, 47 but higher than that of FA-conjugated ZnO or GO nanosheets. 7, 48 Moreover, the resulting Apt@GO@Au-His@a-ZnO@DOX NCs exhibited excellent stability in PBS (pH 7.4) for more than 21 days ( Figure S9 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 used to mimic PTT conditions. As shown in Figure 4E , the accumulative DOX release rate is 11.6% in PBS pH 7.4, while a release rate 30.8% was observed in PBS solution (pH 5.5). This upsurge release rate at pH 5.5 can be explained by the acidic environment that disrupts the binding forces between DOX and NCs. The application of 808-nm laser caused a fast drug release rate up to 75.4%, and the sharp increases occurred at time points of 0.5, 4, and 16 h ( Figure 4E) , with the release rate 20.2%, 13.4%, and 12.7%, respectively. This irradiation-accelerated drug release should be due to the rising temperature that speeded up the molecular movement from NCs nucleus during incubation, indicating the ultimate fate of the DOX released from Apt@GO@Au-His@a-ZnO@DOX.
23
Targeting Efficiencies of Apt@GO@Au-His@a-ZnO@DOX NCs. In addition to release profile, the targeting efficiency of Apt@GO@Au-His@a-ZnO@DOX NCs was next investigated in lung cancer cells, as shown in Figure 5A . To find an optimal cell line for the targeted drug delivery of Apt@GO@Au-His@a-ZnO@DOX NCs, we evaluated the expression of EGFR in both A549 (adenocarcinomic human alveolar basal epithelial) and H522 cells (non-small lung cancer) cell lines. As shown in Figure   5B , a, the expression of EGFR in A549 cell line was higher as compared to H522 cell line. In contrast, EGFR levels in the scrambled control aptamer group ( Figure 5B, b) were much lowered in both A549 and H522 cell lines, presumably resulted from non-specific binding. This result agrees with previous studies about the quantity of EGFR in lung cancer cells. 19 Furthermore, LSCM was utilized to confirm the EGFR antibody targeted delivery of DOX as shown in Figure 5C . Interestingly, DOX fluorescence in the co-incubated A549 cells was obviously higher for Apt@GO@Au-His@a-ZnO@DOX NCs than GO@Au-His@a-ZnO@/DOX NCs, suggesting that GO@Au-His@a-ZnO@DOX NCs was up-taken by A549 cells more inefficiently than Apt@GO@Au-His@a-ZnO@DOX NCs. In addition, the fluorescence intensity of the DOX was quantitatively analyzed by ImageJ software.
The fluorescence intensity of the Apt@Au-His@a-ZnO@GO@DOX NCs was much stronger than GO@Au-His@a-ZnO@DOX NCs ( Figure 5D ), indicating that their 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Interestingly, the cell viability further decreased when the DOX-free nanocarriers, Apt@GO@Au-His@a-ZnO NCs, were applied along with laser irradiation ( Figure 6B , e), indicative that the cell death is not only DOX-dependent, but also a synergetic effect from the whole nanocarriers. Surprisingly, this synergetic effect could be clearly testified using only 100 μg/mL Apt@GO@Au-His@a-ZnO@DOX NCs under laser irradiation, resulting in almost 100 % cell death ( Figure 6B , f). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Apt@GO@Au-His@a-ZnO@DOX NCs were again incubated with A549 cells for 1 h, followed by irradiation with the 808 nm laser at different power densities for 5 min.
After that, MTT assay was performed to incubate the cells for additional 24 h ( Figure   6C ) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 The long circulation time of drugs can be realized by both EPR effect and increased EGFR receptors, resulting in the improved antitumor efficacy. 49, 50 Owing to the fluorescence nature of DOX, it is feasible to investigate the EPR effect of our nanocarriers in mice using the agile intrinsic laser fluorescence, which can avoid external radio or fluorescence. DOX biodistribution study in A549 tumor-bearing mice was subsequently explored by the whole-body fluorescence imaging technique, and images were taken at interval time after intravenous injection of free DOX, Au-His@a-ZnO@DOX NCs, and Apt@GO@Au-His@a-ZnO@GO@DOX NCs (5 mg/kg equivalent DOX). For free DOX, 24 h after injection, its major fraction was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 found in liver, and only a negligible amount of drug was identified in the tumor site.
This implies that free DOX was quickly cleared out by kupffer cell ( Figure 7C ). 42 However , 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Toxicity Evaluation of Combination Therapy. Nanotoxicity has drawn a broad spectrum of concern in clinic therapy. 48 Weight loss is considered as the effective index to evaluate the toxicity. As such, we measured the body weight of mice in all groups. As shown in Figure 9B , mice weight between the treatment and negative groups show no significant difference. In addition, no abnormality was identified in the normal tissues and no obvious toxicity of our nanosystem was detected in the organs according to the result of H&E staining ( Figure 9A ). Besides, organ indices were measured to assess the general toxicity. It is worth mentioning that the increasing organ index is strongly correlated with its strengthened function, congestion, proliferation, or swelling while the decrease presented the opposite changes. The comparison between control and Apt@GO@Au-His@a-ZnO@DOX NCs (L+) groups ( Figure  9C ) showed that applying Apt@GO@Au-His@a-ZnO@DOX NCs (L+) caused neither toxicity nor any side effects. In vivo long-term tissue biodistribution of Apt@GO@Au-His@a-ZnO@DOX NCs in mice was detected using ICP-MS, as shown in Figure S11 . By monitoring the presence of Au element in the tissue and organs, it was found that the NCs could be generally expelled from the body as time prolonged.
Furthermore, the toxicity of Apt@GO@Au-His@a-ZnO@DOX NCs (L+) was determined by biochemical analysis of mice blood. As shown in Figure 9D , E, the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Apt@GO@Au-His@a-ZnO@DOX NCs (L+) group caused no obvious increase in levels of lactate dehydrogenase (LDH) and creatine kinase (CK), which are important parameters of heart function, suggesting that the nanosystem could reduce the side effect of DOX. In addition, comparing with free DOX, the use of Apt@GO@Au-His@a-ZnO@DOX NCs (L+) caused no damage to liver function (aspartate aminotransferase (AST), alanine aminotransferase (ALT)) ( Figure 9F, G) , and kidney function (creatinine, uric acid (UA)) ( Figure 9H, I ). Therefore, all toxicity study proved that Apt@GO@Au-His@a-ZnO@DOX NCs (L+) has good biocompatibility, suggesting them as effective and safe nanomedicine to treat lung cancer. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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